Stock AnalizVertex Pharmaceuticals Inc. / MA (VRTX) earnings for the quarter ended September 2026: EPS misses estimates
Vertex Pharmaceuticals Inc. / MA reported results for the quarter ended September 2026 on November 2, 2026. Adjusted earnings per share came in at $4.76 against the analysts’ average forecast of $4.78, a miss of 0.5%.
Revenue for the quarter was $3.44 billion, up 11.8% from $3.08 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 5.0% on the first trading day after the report.
The last four quarters
Vertex Pharmaceuticals Inc. / MA has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $4.76 | $4.78 | −0.5% | +12% | −5.0% |
| Jun 2026 | $4.73 | $4.75 | −0.3% | +12% | +0.3% |
| Mar 2026 | $4.47 | $4.31 | +3.8% | +8% | +0.1% |
| Sep 2025 | $4.80 | $4.58 | +4.9% | +11% | −0.9% |
What comes next
Analysts expect EPS of $4.10 for the next quarter on average and $18.12 for the fiscal year ending December 31, 2026.
The average analyst price target is $595.36, 11% above the current price of $538.60.
Valuation and score
Vertex Pharmaceuticals Inc. / MA scores 2.4 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 34.7, and its intrinsic value under moderate assumptions is about 53% below the current market value. Full Vertex Pharmaceuticals Inc. / MA analysis with 10 years of financials
Frequently asked questions
What was Vertex Pharmaceuticals Inc. / MA’s EPS for the quarter ended September 2026?
$4.76 adjusted per share, against an analyst consensus of $4.78.
How much revenue did Vertex Pharmaceuticals Inc. / MA report?
$3.44 billion, up 11.8% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.